Complementâ  induced activation of MAPKs and Akt during sepsis: role in cardiac dysfunction by Fattahi, Fatemeh et al.
THE
JOURNAL • RESEARCH • www.fasebj.org
Complement-induced activation of MAPKs and Akt
during sepsis: role in cardiac dysfunction
Fatemeh Fattahi,*,1 Miriam Kalbitz,†,1 Elizabeth A. Malan,* Elizabeth Abe,* Lawrence Jajou,*
Markus S. Huber-Lang,† Markus Bosmann,‡ Mark W. Russell,§ Firas S. Zetoune,* and Peter A. Ward*,2
*Department of Pathology and §Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor,
Michigan, USA; †Department of Orthopaedic Trauma, Hand, Plastic, and Reconstructive Surgery, University Hospital of Ulm, Ulm, Germany;
and ‡Center for Thrombosis and Hemostasis, University Medical Center, Mainz, Germany
ABSTRACT: Polymicrobial sepsis in mice causes myocardial dysfunction after generation of the complement ana-
phylatoxin, complement component 5a (C5a). C5a interactswith its receptors on cardiomyocytes (CMs), resulting in
redox imbalance and cardiac dysfunction that can be functionally measured and quantitated using Doppler
echocardiography. In this reportwehaveevaluatedactivationofMAPKsandAkt inCMsexposed toC5a invitroand
after cecal ligation and puncture (CLP) in vivo. In both cases, C5a in vitro caused activation (phosphorylation) of
MAPKsandAkt inCMs,which required availability ofbothC5a receptors.Using immunofluorescence technology,
activationofMAPKsandAkt occurred in left ventricular (LV)CMs, requiringbothC5a receptors,C5aR1 and -2.Use
of awater-soluble p38 inhibitor curtailed activation in vivo ofMAPKs andAkt in LVCMsaswell as the appearance
of cytokines and histones in plasma from CLP mice. When mouse macrophages were exposed in vitro to LPS,
activation ofMAPKs andAkt also occurred. The copresence of the p38 inhibitor blocked these activation responses.
Finally, the presence of the p38 inhibitor in CLPmice reduced the development of cardiac dysfunction. These data
suggest that polymicrobial sepsis causes cardiac dysfunction that appears to be linked to activation ofMAPKs and
Akt in heart.—Fattahi, F., Kalbitz,M., Malan, E. A., Abe, E., Jajou, L., Huber-Lang, M. S., Bosmann,M., Russell, M.
W., Zetoune, F. S., Ward, P. A. Complement-induced activation of MAPKs and Akt during sepsis: role in cardiac
dysfunction. FASEB J. 31, 4129–4139 (2017). www.fasebj.org
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Inhumans, sepsis often leads tomyocardial dysfunction in
at least 40% of patients, and it has been associated with
mortality rates as high as 70% (1–3). In rodents and hu-
mans, activation of the complement system during sepsis
results in robust production of the complement anaphy-
latoxin, complement component 5a (C5a) (4), at levels that
correlate with the severity of sepsis (5). Absence or block-
ade of either C5a receptor (C5aR) substantially improved
survival rates in mice after cecal ligation and puncture
(CLP)-induced sepsis (6). Addition of recombinant C5a to
rat or mouse cardiomyocytes (CMs) caused CM dysfunc-
tion, involving both contractility and relaxation (7, 8).
Likewise, CMs isolated fromCLPhearts showed increased
levels of C5aR1 (8). These data suggest that C5a plays an
important role in the development of harmful outcomes of
sepsis, especially involving the heart, through its receptors
(C5aR1 and -2) on CMs (9).
Interaction of C5a with its receptors leads to many
pleiotropic effects, including the release of cytokines
and chemokines and recruitment of inflammatory cells
(10). In certain circumstances, C5a-C5aR interactions
can also result in the activation of signaling pathways in
CMs including MAPKs, which in turn modulate tran-
scriptional factors that amplify gene expression (11).
There are 3 well-defined MAPK pathways: ERK-1/2,
JNK-1/2, and p38 (12). MAPK signaling efficiency and
specificity are modulated by protein–protein interac-
tions between individual MAPKs and the docking
motifs in cognate binding partners (13). Important sig-
naling pathways regulating responses of the cells to the
infection and stress are via MAPKs (14). MAPKs have
emerged in many cell types as important signaling path-
ways in a variety of biologic processes, such as in-
flammation, cell growth, cell differentiation, cell cycle, and
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cell death and during ischemia–reperfusion (I/R) injury,
sepsis, and many other diseases (15, 16).
In the heart, I/R injury and ischemic heart failure has
been shown to activate signaling cascades of the MAPK
family (17, 18). Once activated, MAPKs phosphorylate
several downstream targets (other protein kinases and
transcription factors) (16). The activation of MAPKs has
been proposed to be initiallymediated via the activation of
members of the Src family tyrosine kinases through a Shc/
Grb2/Ras signaling cascade (17). In addition to MAPK,
Ras-GTP has been shown to bind and activate PI3K (17,
19). PI3K activation phosphorylates and activates down-
streamof a serine/threonine-specific protein kinase called
Akt (also known as PKB). Akt is activated by a variety of
growth factorsandcellular stressesviaphosphorylationon
threonine 308 (T308) and serine 473 (S473) residues (17).
The coinvolvement of MAPK and Akt signaling path-
ways has been described in I/R injuries. We found coin-
volvement of MAPK and Akt signaling in I/R injury in
liver (20). Several other reports showed involvement of
both MAPK and Akt signaling pathways in cardiac I/R
injury (21–26). To our knowledge, there are few, if any,
published reports about the coinvolvement of MAPKs
andAkt signaling pathways in cardiac defects after sepsis.
In the current study we investigated activation (phos-
phorylation) of MAPKs (p38, ERK-1/2, and JNK-1/2)
andAkt inmouse CMs after CLP or after in vitro exposure
to C5a. We also used the water-soluble inhibitor of p38 to
characterize the linkage between MAPK activation and
development of cardiac dysfunction during sepsis.
MATERIALS AND METHODS
Animals
Allprocedureswereperformedaccording to theGuide for theCare
and Use of Laboratory Animals (National Institutes of Health,
Bethesda, MD, USA) and were approved by the University of
Michigan Committee on Use and Care of Animals. Specific
pathogen-free male Sprague-Dawley rats (300–350 g) (Harlan
Laboratories, Indianapolis, IN, USA) and male C57BL/6 mice
(8–10 wk, 25–30 g) (The Jackson Laboratories, Bar Harbor, ME,
USA) were used in this study. Some experiments were also per-
formed in male C57BL/6 mice from our own C5aR12/2 and
C5aR22/2 breeding colonies at the University of Michigan. The
generation of C5aR12/2 andC5aR22/2mice has been described
in refs. 27 and 28.
Experimental sepsis
Midgrade CLP (;50% survival after 7 d) was performed in this
study, according to a published procedure (29, 30). The animals
were euthanized 8, 16, 24, or 48 h after CLP.
Isolation of CMs
The isolation of young adult CMs was performed with rat and
mouse hearts (7, 30, 31). After isolation, we increased in a step-
wise manner the Ca2+ concentrations in the medium, to achieve
physiologic levels of Ca2+. These procedures avoid sarcoplasmic
overload of Ca2+. Supplemental Fig. 1 shows the morphology
of isolated rat CMs, indicating their rectangular shape with a
distinct rod-shaped appearance and clear striations. In addition,
we cultured the isolated CMs to let them be recovered from the
stresses and damage that occurred during the enzymatic di-
gestion and physical disruption of the isolation procedure. We
did not note changes in the cell contours of CMs after exposure to
agonists such asC5a, butwedidnot ruleout subtle changes, such
asmembranerufflingafter exposure toC5a.Wehave shownhow
these CMs respond to histones (31) or C5a (7), which were not
toxic for the cells (no apoptosis or release of LDH).
Permeabilization of CMs and intracellular
antibody staining
For assessment of intracellular staining by flow cytometry, CMs
were fixed in0.25%paraformaldehydeat4°C for30min.Thecells
were permeabilized with 1% saponin (Sigma-Aldrich, St. Louis,
MO, USA) at room temperature for 60 min. Incubation with the
antibodies was performed in the presence of 0.1% saponin in the
dark at room temperature for 30 min. The following conjugated
antibodies from BD Biosciences (Franklin Lakes, NJ, USA) were
used to evaluate MAPK phosphorylation: BD Phosflow Alexa
Fluor 488 mouse anti-ERK-1/2 (p202/pY204); BD Phosflow
Alexa Fluor 488 mouse anti-Akt (pS473), clone: M89-61; and BD
Phosflow PE mouse anti-p38 MAPK (pT180/pY182). Un-
conjugatedBDPhosflowpolyclonal rabbit anti-JNK-1/2 (pT183/
pY185) antibody was used in combination with fluorescein
(FITC)-conjugated AffiniPure F(ab9)2 fragment goat anti-rabbit
IgG (H+L) purchased from Jackson ImmunoResearch (West
Grove, PA, USA). In Supplemental Fig. 2A–D are examples of
flow cytometry graphs showing fluorescence-activated cell-
sorting profiles for each antibody in rat CMs.
Immunostaining of frozen left ventricular sections
for MAPKs
All immunostaining was performed on fresh-frozen 4-mm–thick
left ventricular (LV) sections of mouse heart tissue, embedded in
optimal cutting temperature compound (Fisher Healthcare,
Houston, TX,USA). The following individual ormultiple primary
antibodieswereused:monoclonal anti-troponin-Tcardiac isoform
Ab-1 (clone 13-11; Lab Vision; Thermo Fisher Scientific,Waltham,
MA, USA), rabbit anti-phospho-p44/42 MAPK (ERK-1/2)
(Thr202/Tyr204) antibody (Cell Signaling Technology, Danvers,
MA, USA), and rabbit anti-phospho-p38 (Thr180/Tyr182) anti-
body (Cell Signaling Technology). Secondary antibodies were as
follows: anti-mouse IgG conjugated to Alexa Fluor 647 and anti-
rabbit IgG conjugated to Alexa Fluor 488 (both from Jackson
ImmunoResearch Laboratories). The slides were mounted with
ProLong Gold antifade reagent containing DAPI (Thermo Fisher
Scientific) and viewedwith anAxio fluorescencemicroscopewith
Axio Vision software (Zeiss, Jena, Germany). Negative staining
controls lacking primary antibody were always performed.
Isolating and treating peritoneal exudatemacrophages
Mouse peritoneal exudate macrophages (PEMs) were isolated
4 d after the injection of 1.5 ml 2.4% thioglycolate, i.p. (Thermo
Fisher Scientific), according to our published procedure (32, 33).
PEMs were treated with LPS (100 ng/ml, 1 h at 37°C), with or
without p38 inhibitor.
Cytokine and histone ELISAs
Cytokine (IL-6, IL-1b, andTNF)ELISAswere fromR&DSystems
(Minneapolis, MN, USA) and performed per the manufacturer’s
recommendations. The histone ELISA (Cell Death Detection
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ELISA)was fromRoche (Indianapolis, IN, USA). Purifiedmixed
calf thymus histoneswere used to generate standard curves (34).
Bio-Plex phosphoprotein assay
The Bio-Plex phosphoprotein assay was used to detect the pres-
ence of phosphorylated p38, ERK-1/2, JNK-1/1, and Akt in
PEMs after the exposure to LPS (100 ng/ml, 1 h at 37°C). The
assay kit and the phosphoprotein testing reagent kit (Bio-Rad
Laboratories, Hercules, CA, USA) were used according to the
manufacturer’s protocol.
Reagents
The reagent used in this study, recombinant rat (rr)C5a, was pro-
ducedbyus (8, 35).Thechemicalsused forpreparationof solutions
for CM isolation and LPS were purchased from Sigma-Aldrich.
In our first set of experiments, DMSO-soluble inhibitors for
MAPKs (p38, JNK-1/2, and ERK-1/2) and Akt were used. Our
functional data, obtained with Doppler echocardiography (echo
Doppler), from septic mice treated with one of these inhibitors
showed the same response as themice treatedwithDMSO alone
(data not shown), indicating the antioxidant effects of DMSO, per
se. To avoid any artificial antioxidant properties of the other
DMSO-soluble MAPK inhibitors (36), in our second set of ex-
perimentsweusedawater-solubleMAPKinhibitor that, so far, is
available only for p38. Water-soluble salt of p38 inhibitor (SB
203580), purchased from Tocris Bioscience (Bristol, United
Kingdom), was therefore used in the current study. For in vivo
experiments, 20 mg/kg, i.p. of the inhibitor was used 2 h before
inducing CLP to study the effects of this inhibitor on the activa-
tion pattern occurring after sepsis, by measuring histone and
cytokines (IL-6 and -1b) levels in the plasma, aswell as activation
of MAPK and Akt in the heart tissue. For in vitro experiments,
different doses (5–50 mM) of this inhibitor were used to find the
half maximum inhibitory concentration (IC50) for further in vitro
experiments.
Echocardiography
Echocardiography was performed, according to a published
procedure (7, 30, 31), by a registered echocardiographerwhowas
blindedto the treatmentgroupsofmice.Wild-type (WT)C57BL/6
mice were weighed and anesthetized with inhaled isoflurane.
Imagingwas performedwith aVevo 770High-Resolution InVivo
Imaging System (Visualsonics, Toronto, ON, Canada) equipped
with an RMV-707 30-MHz RMV (up to 45MHz) scan head (real-
time visualization). Details of measuring systolic and diastolic
parameters by echoDoppler are described in ourprevious reports
(7, 30, 31). Imaging was performed before and 8 h after CLP.
Statistical analysis
Data were expressed asmeans6 SEM and analyzedwith Prism 7
graphing and statistical analysis software (GraphPad, Inc., La
Jolla, CA, USA). Significant differences between groups were
determined by 1-wayANOVAorStudent’s t test, as appropriate.
Significance was set at P, 0.05.
RESULTS
C5a-induced activation of Akt and MAPKs
in CMs
Rat cardiomyocytes were cultured in PBS buffer (control)
or in the presence of recombinant rat (rr)C5a (1mg/ml) at
37°C for various times (Fig. 1). Based on flow cytometry
analysis of saponin-permeabilizedCMs, phosphorylation
of Akt and MAPKs occurred as a function of time
of exposure to C5a. We used mAbs that had as tar-
gets phosphoserine, phosphothreonine, or phosphotyro-
sine. In the case of Akt, phosphorylation was clearly
evident by 60 min, persisting for up to 120 min, and
Figure 1. Time courses for C5a-induced (1 mg rrC5a/ml) in vitro activation (phosphorylation) of Akt (A, E) and the 3 MAPKs
(p38, B, F; ERK-1/2, C, G; and JNK-1/2, D, H) in rat CMs. Using antibodies to phosphoamino acids in Akt or in MAPKs, end
points were determined by ﬂow cytometry in saponin-permeabilized rat CMs. A–D) On the vertical axes are the antibody targets
(phosphoserine, phosphothreonine, or phosphotyrosine). On the horizontal axes are the time courses (min) of activation. E–H)
The time courses (h) for CLP-induced activation (phosphorylation) of Akt and MAPKs in permeabilized rat CMs as a function of
time after CLP. MFI, mean ﬂuorescence intensity, indicating levels of phospho-MAPK and phospho-Akt. Ctrl, control CMs from
sham-treated rats. Data are expressed as means 6 SEM (n $ 6 for all time groups). *P , 0.05.
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thereafter decreasing (Fig. 1A). In the case of p38, there
was progressive phosphorylation from 60–120 min, fol-
lowed by rapid decline after 4 h (Fig. 1B). In the case of
ERK-1/2, phosphorylation peaked at 60 and 90 min, fol-
lowed by a decline (Fig. 1C). Phosphorylation of JNK-1/2
was not found until 120 and 240 min after C5a exposure
(Fig. 1D). Clearly, CMs exposed in vitro to C5a (1 mg/ml)
were activated as a function of time of exposure toC5a for
all 3 MAPKs, as well as for Akt.
Figure 1E–H demonstrates activation in CMs of Akt
and all 3 MAPKs as a function of time after CLP (8–48 h).
Phosphorylation of Akt peaked at 16 and 24 h after CLP,
followed by a decline (Fig. 1E). A peak in phosphorylation
of p38 occurred 16 h after CLP, followed by a decline (Fig.
1F). For activation of ERK-1/2 (Fig. 1G), the pattern was
similar to that for p38, peaking at 16 h. For JNK-1/2 (Fig.
1H), activationafterCLPalsopeakedat 16h, followedby a
decline.Accordingly,CLP caused activation ofAkt aswell
asp38,ERK-1/2, and JNK-1/2 inCMsas a functionof time
after the onset of sepsis.
CLP-induced activation of Akt and MAPKs in
LV CMs and requirement for C5aRs
For these experiments, frozen LV sections of mouse hearts
were obtained from WT control mice before and, where
indicated, from C5aR-knockout (KO) mice, 16 h after CLP.
There was virtually no staining in WT control (sham-
treated) hearts, but in WT hearts 16 h after CLP, intense
green fluorescence indicated presence of phospho-ERK-1/
2, which was greatly diminished in hearts from 16 h CLP
mice lacking either C5aR (Fig. 2A, top). The frozen LV
sections revealed intense red fluorescence for troponin-T
(TnT) and similar patterns of green staining for phospho-
ERK-1/2 16 h after CLP (Fig. 2A, bottom). Yellow-green
fluorescence and blue nuclear (DAPI) stain, indicated a
mergerof fluorescence-labeledTnTandphospho-ERK-1/2.
CLP was associated with intense green staining for
phospho-p38 in LV CMs. In C5aR-KO CLP mice, the
fluorescence for activated p38 was barely detectable (Fig.
2B, top). Therewas intense red fluorescence for TnT, green
fluorescence for phospho-38, with the merged image
showing blue fluorescence for nuclear staining and
yellow-green fluorescence (Fig. 2B, bottom). CLP induced
staining of green fluorescence for phospho-Akt and for
phospho-JNK-1/2 (Fig. 2C,D). In each case, the absence of
C5aRs caused reduced evidence for activation of Akt and
JNK-1/2 after CLP. Taken together, the data indicate that,
after CLP, C5a and its receptors activate Akt and MAPKs
in CMs,whichmay be linked to the development of septic
cardiomyopathy.
Reduced plasma histones IL-6 and IL-1b in
CLP mice pretreated with water-soluble
p38 inhibitor
Eight hours afterCLP, 10CLPWTmice that received 1.0ml
PBS, i.p., and 10 CLP mice treated with the p38 inhibitor
(SB203580) were compared for levels of plasma histones
and cytokines,which are reliableplasmabiomarkers for the
intensity of sepsis (31) (Fig. 3). The time point of 8 h after
CLP was selected, because, at this time point, there is clear
dysfunctionof hearts basedon echoDoppler parameters (7,
30, 31). The mice received the water-soluble p38 inhibitor
(20 mg/kg in a volume of 1.0 ml PBS, i.p.), which was
injected 2 h before the onset of CLP. The positive reference
group received 1.0 ml PBS, i.p. 2 h before CLP. At 8 h after
CLP, plasma (using acid-citrate-dextrose as the anticoagu-
lant)wasobtained fromthe inferiorvenacavaandanalyzed
byELISA forhistoneand cytokine content.Nonmeasurable
levels of histones and cytokines were present in plasma
beforeCLP (data not shown). Therewas a 58% reduction in
plasma levels of histones in CLP mice that received the
water-soluble p38 inhibitor (Fig. 3A), when compared to
theCLPgroup receivingPBS. Therewas a 38% reduction in
the amount of plasma IL-6 (Fig. 3B) and a 45% reduction
in plasma IL-1b (Fig. 3C) in CLP mice pretreated with the
water-soluble inhibitor of p38.Wehave recently shown (31)
that reduced plasma histone levels also occurred in CLP
mice that lackedeitherof the twoC5aRsor inmice thatwere
devoid of the nucleotide-binding domain and leucine-rich
repeat pyrin domain–containing protein-3. In such cases,
the KO mice were protected from the full development of
cardiac dysfunction after CLP (as demonstrated by echo
Doppler parameters) (7), indicating that the sepsis-induced
cardiac defects also require participation of nucleotide-
binding domain and leucine-rich repeat pyrin domain–
containing protein-3 and both C5aRs.
Ability of the p38 inhibitor to suppress
in vitro activation of MAPKs and Akt in
LPS-stimulated PEMs
Mouse PEMs (1 3 106) were exposed to PBS buffer (neg-
ative control) or to LPS (100 ng/ml) for 1 h at 37°C, after
which cells were assessed by the Bio-Plex phosphoprotein
assay for activation of p38, ERK-1/2, JNK-1/2, and Akt,
using the antibodies described in Fig. 1. LPS caused acti-
vation of Akt and all 3 MAPKs (Fig. 4A–D). The most
robust activation involved ERK-1/2 (nearly a 13-fold in-
crease). In the absence of detailed studies (LPS dose re-
sponses) it is premature to come to definitive conclusions
about the rank order of MAPK and Akt activation. LPS
activation of PEMs included a 4-fold increase in phospho-
p38 (Fig. 4A), a 13-fold increase in ERK-1/2 (Fig. 4B), anda
7-fold increase in phospho-JNK (Fig. 4C), along with a
small increase in phospho-Akt (Fig. 4D).
MousePEMswereactivated invitrowithLPS(100ng/ml)
for 4 h at 37°C in the presence of (1 h preincubation)
increasing amounts (5–50 mM) of the water-soluble p38
inhibitor (Fig. 4E, F). There was a dose-dependent re-
duction of IL-6 and -1b in cell supernatant fluids that
ranged from 10 to 17 mM of the water-soluble inhibitor,
allowing us to calculate the IC50 of the p38 inhibitor for
use in the flow cytometry experiments (Fig. 4G–K).
We used PEMs exposed to buffer (negative control) or to
LPS (100 ng/ml) in the absence or presence (1 h pre-
incubation) of the 20mMwater-soluble p38 inhibitor (a dose
close to its IC50;Fig. 4G–K).Cellswere then incubatedat37°C
for 1hwithLPS.AfterLPS treatment, cellswere incubated in
cytofix/cytoperm solution (BD Cytofix; BD Biosciences)
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for 20 min and permeabilized with Perm Buffer III (BD Bio-
sciences) for intracellular staining. Stained cells with BD
Phosflow MAPK and Akt antibodies were fixed with 2%
paraformaldehyde and evaluated for phosphoproteins by
flow cytometry, as described elsewhere (37, 38). Typical
traces produced by flow cytometry included buffer-treated
cells (negative control),LPS-treatedcells, andcells exposed to
both LPS and the water-soluble p38 inhibitor (20 mM). Ac-
tivation of p38 was clearly visible by the shift to the right
of cells exposed to LPS (Fig. 4G). It was also clear that
A
Troponin-T
B
C
D
Wt CtrlP Wt 16hr CLP C5aR1-/- 16hr CLP C5aR2-/- 16hr CL
Phospho-ERK1/2
(40x)
Co-staining TnT
and Phospho-p38
Wt 16hr CLP
(100x)
Phospho-ERK1/2 DAPI Merge
Phospho-p38
(40x)
Co-staining TnT and
Phospho-ERK1/2
Wt 16hr CLP
(100x)
Troponin-T
Wt CtrlP Wt 16hr CLP C5aR1-/- 16hr CLP C5aR2-/- 16hr CL
Phospho-ERK1/2 DAPI Merge
Wt CtrlP Wt 16hr CLP C5aR1-/- 16hr CLP C5aR2-/- 16hr CL
Phospho-Akt
(40x)
Phospho-JNK1/2
(40x)
Figure 2. Phospho-MAPKs and Akt before (Ctrl, control) and 16 h after CLP, in frozen LV sections of WT mouse hearts or C5aR-
KO mouse hearts. A) Phospho-ERK-1/2 before (Ctrl) or 16 h after CLP. Red: TnT; green: phospho-ERK-1/2; blue: DAPI-stained
nuclei; yellow-green: merged image of TnT and ERK-1/2 labeling in CMs. A) Top: phospo-ERK-1/2 revealed green staining of
CMs 16 h after CLP. The staining was markedly reduced in CLP CMs from C5aR-KO mice. B) Phospho-p38 images were very
similar to those for phospho-ERK-1/2. C, D) Phospho-Akt (C) and phospho-JNK-1/2 (D) 16 h after CLP in WT CMs and CMs with
and without C5aR1 and -R2. There were marked reductions in phospho-Akt and phospho-JNK-1/2 in frozen LV sections from
C5aR-KO mice (n $ 3 for each group of frozen sections).
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the inhibitor interfered with the rightward shift.
Activation of the p38 inhibitor was reduced in activa-
tion (phosphorylation) of MAPKs and Akt in PEMs, with
reductions varying from 46 to 64% (Fig. 4H–K). Taken
together, the evidence showed that the water-soluble
inhibitor p38 also suppressed activation of all 3 MAPKs
and Akt in PEMs exposed to LPS.
Ability of water-soluble inhibitor p38 to
reduce activation of MAPKs in LV CMs 16 h
after CLP and reduction of cytokine release
from LPS-stimulated PEMs
Using protocols similar to those in Fig. 2, the immunoflu-
orescence images in Fig. 5 indicate that LV CMs 16 h after
CLP demonstrated activation of MAPKs (Fig. 5A, C, E)
and Akt (Fig. 5G), whereas LV CMs in mice treated with
thewater-solublep38 inhibitor showedvery little evidence
of kinase activation after CLP (Fig. 5B, D, F, H), although
nuclear staining with DAPI was evident. These data are
consistent with those in Fig. 3, inwhichmice 8 h after CLP
showed reduced plasma levels of extracellular histones
IL-6 and -1b. When combined, the data in Fig. 5 indicate
that the water-soluble p38 inhibitor inhibits activation of
all 3 MAPKs as well as Akt in mice that undergo CLP.
The p38 inhibitor preserves cardiac
performance after CLP
As has been reported, CLP induces numerous defects in
echo Doppler parameters of cardiac performance (7, 30).
In Fig. 6, 8 h after CLP, there was a significant reduction in
heart rate, LV stroke volume, and cardiac output and an
increase in ejection fraction (Fig. 6A–D). In mice injected
intraperitioneally with the p38 inhibitor 2 h before CLP,
there was modest improvement in systolic performance.
Mice receiving the p38 inhibitor had a reduction in LV
stroke volume and an increased ejection fraction after CLP
that was similar to that noted in control mice (Fig. 6B, D).
Injection of the p38 inhibitor resulted in attenuation of the
decline in cardiac output after CLP, but there was no sig-
nificant difference in the post-CLP cardiac output of ani-
mals that did or did not receive the p38 inhibitor (Fig. 6C).
The preservation of heart rate after CLP by p38 inhibition
reached clinical significance (Fig. 6A). Like cardiac systolic
function, cardiac diastolic function was impaired 8 h after
induction of CLP. Isovolumic relaxation time (IVRT) and
mitral valve (MV) deceleration time were prolonged, and
the E-wave (early)/A-wave (late) diastolic filling velocity
(E/A) ratio was reduced, suggesting impaired diastolic
function 8 h after CLP (Fig. 6E, G, H). Injection of a p38
inhibitor before CLP resulted in preservation of diastolic
performance: IVRT 17.4 ms (p38 control) vs. 17.8 ms (p38
injected) (Fig. 6E); E/A ratio: 1.4 (p38 control) vs. 1.2 (p38
injected) (Fig. 6G); andMVdeceleration time: 11.7ms (p38
control) vs. 11.2 ms (p38 injected) (Fig. 6H). These data
suggest that the water-soluble inhibitor of p38 greatly
suppressed sepsis-induced development of cardiac dys-
function.Unfortunately, the lack of commercially available
p38-KO mice prevented experiments that would have de-
finitively determined the effects of its absence on devel-
opment of cardiac dysfunction after sepsis.
DISCUSSION
In the current report, we showed C5a-dependent activa-
tion (phosphorylation) ofMAPKs andAkt inmouse heart
after polymicrobial sepsis. In our earlier studies, we found
evidence of involvement ofAkt orMAPKs signaling in the
heart and phagocytes in CLP-induced sepsis (11, 39, 40).
Our data have suggested that the PI3-K/Akt signaling
pathway controls various C5a-mediated effects on neu-
trophil and monocyte innate immunity during experi-
mental sepsis (39). We have shown the ability of C5a to
cause activation of ERK-1/2 and p38 MAPK signaling
pathways on neutrophils during sepsis in a C5a/C5aR-
dependent manner (40). In the current study, we expand
our data to investigate activation ofMAPKs (p38, ERK-1/
2, and JNK-1/2) and Akt in the CMs from CLP mice or
after in vitro exposure to C5a.
After in vitro exposure of CMs to C5a, it was clear that
there was activation (phosphorylation) of MAPKs (p38,
ERK-1/2, and JNK-1/2) as well as Akt (Fig. 1A–D). These
responseswerebothtime-dependentandC5aconcentration
dependent. These data suggest that C5a plays a role in
MAPK and Akt signaling pathways in CMs. Furthermore,
flow cytometric analysis of CMs revealed activation of
MAPKs andAkt in LVCMsas a function of time after onset
of CLP (Fig. 1E–H), suggesting the activation ofMAPK and
Akt signaling pathways after CLP in CMs.
Figure 3. Treatment of CLP mice with a water-soluble p38 inhibitor, which was given 2 h before CLP. As measured by ELISA,
there were sharp reductions 8 h after CLP in plasma biomarkers of sepsis: extracellular histones (A), IL-6 (B), and IL-1b (C)
(n = 10 mice per marker). Data are expressed as means 6 SEM.
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Figure 4. Phosphorylation of mouse PEMs (1 h at 37°C) caused by LPS (100 ng/ml). A–D) Bio-Plex phosphoprotein assay analysis
of intracellular phospho-MAPKs p-p38 (A), p-ERK1/2 (B), and p-JNK (C) or p-AKT (D). Neg Ctrl, negative control. E, F) Dose
response test of water-soluble p38 inhibitor (5–50 mM), in which the IC50 was used, indicated a dose-related reduction in release
of IL-6 (E) and TNF (F). G–K) In vitro reductions in phospho-MAPKs and Akt in PEMs exposed to LPS in the absence or
presence of 20 mM water-soluble inhibitor of p38. G) Typical example of PEMs exposed to buffer (neg ctrl) or to LPS in the
presence or absence of the p38 inhibitor, using ﬂow cytometry as the end point for phospho-Akt or phospho-MAPKs, as described
in Fig. 1. H–K) Levels of mean ﬂuorescence intensity (MFI) indicating the levels of phospho-MAPKs p-p38 (H), p-ERK1/2 (I),
and p-JNK (J) or p-AKT (K) in PEMs exposed to LPS in the absence or presence of 20 mM water-soluble inhibitor of p38. Data are
expressed as means 6 SEM (n $ 5 samples per group). *P , 0.05.
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Our immunofluorescent analysis of frozen LV sections
ofWTmousehearts confirmed these findings, as it showed
theactivationofMAPKsandAkt inCMsafterCLP.Hearts
from mice genetically deficient in either C5aR-1 or -2
revealed that activation of MAPKs and Akt in CMs re-
quired availability of both C5aRs (Fig. 2). These data
suggest that the activation of MAPKs and Akt in a septic
heart is C5aR dependent. These findings are in line with
the previous reports of neutrophils or macrophages stim-
ulated with C5a or LPS (41–43).
Our immunofluorescence staining showed localization
ofactivatedAktand JNK-1/2 (Fig. 2C,D) inbothcytoplasm
andnucleus,but in thecaseofp38andERK-1/2thestaining
was only cytosolic and not nuclear (Fig. 2A, B). We did not
studyanyspecific isoformofp38,but the literature reported
that localization of p38 is likely to be isoform specific. For
p-P38 p-Aktp-JNK1/2p-ERK1/2
PBS
P38
Inhibitor
A
B
C
D
E
F
G
H
Figure 5. Blockage of activation of MAPKs by water-soluble p38 inhibitor 16 h after CLP, determined with techniques similar to
those described in Fig. 2. A, C, E, G) At 16 h after CLP, CMs demonstrated phosphorylation of MAPKs p38 (A), ERK1/2 (C), and
p-JNK (E) and AKT (G). Green: MAPK; blue: DAPI. B, D, F, H) Pre-CLP administration of the p38 inhibitor blocked activation in
CMs of all 3 MAPKs (p38, B; ERK1/2, D; and p-JNK, F) and AKT (H). (n = 4 separate samples in each group).
Figure 6. Echo Doppler parameters in hearts of mice before (WT control) and 8 h after CLP. Heart rate (A), LV stroke volume
(B), cardiac output (C), LV ejection fraction (D), IVRT (E), LV volume diastole (F), E/A ratio (G), and MV deceleration time
(H). Data are expressed as means 6 SEM (n $ 6 mice per group).
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example, the p38-aMAPK has been identified as a nuclear
protein in its inactive state, bound to its substrate
MAPKAPK-2 (MAPK-activated protein kinase-2). After
activation, p38-a MAPK phosphorylates MAPKAPK-2,
and this phosphorylation masks a nuclear localization sig-
nal inMAPKAPK-2, resulting in the export of bothproteins
to the cytoplasm (44).Court et al. (45) showedboth cytosolic
and nuclear localization of p38 family members on CMs.
They showed nonnuclear localization of p38-g (stress-
activatedprotein kinase-3) staining on rat andmouse heart.
In fact, inactive p38-g is cytoplasmic compared to the nu-
clear localization of inactive p38-a/b (44, 45). The locali-
zation of ERK-1/2 can be dependent on the intensity of the
activation (phosphorylation). Rubinfeld et al. (46) showed
that overexpression of ERK-1/2 in cells frequently drives
them into the nucleus, presumably by overwhelming cy-
tosolic binding sites. They showed that coexpression of the
ERK-2 with its upstream activator, MEK-1, results in cyto-
solic retention of the ERK-2, which is the result of its asso-
ciation with MEK-1 and is reversed upon stimulation (46).
In earlier report, Zheng et al. (47) showed that ERK is
phosphorylated and activated in the cytoplasm, and the
activated ERK could subsequently translocate into the nu-
cleus and phosphorylate its nuclear substrates. They
showedMEK(MAPKorERK) is localizedexclusively in the
cytoplasm, as measured by indirect immunofluorescence,
subcellular fractionation, and detergent permeabilization
techniques. In contrast to ERK, MEK was not translocated
into the nucleus when cells were treated with mitogens,
indicating that ERK is phosphorylated and activated by
MEK in the cytoplasm (47). They compared their immu-
nofluorescence findings with other reports, of which some
showed that both cytoplasm and nucleus localization of
ERK depends on the cell types.
Most of the studies on MAPK signaling pathways are
descriptive, and it is difficult to determine how the sig-
naling pathways between individual MAPKs and their
interactions work. One of the ways to study MAPK sig-
naling pathways is using MAPK inhibitors. In Fig. 3, we
used the p38 inhibitor to see whether its blocking can
reduce the adverse outcome after sepsis as p38 MAPK is
suggested to be a key signaling molecule in septic lung
injury (48) and has been shown to be a therapeutic target
in inflammatory diseases (14). There are also substantial
data in mice, showing that inhibition of p38 MAPK may
have protective effects against development of cardiac
hypertrophy and dysfunction (49), as well as in other
diseases such as acute liver failure (50) and arthritis (51).
Our studies involved systemic administration of a water-
soluble p38 inhibitor, avoiding the difficulties of artifacts
inducedbyMAPK inhibitors that require solubilization of
inhibitors in DMSO, which has strong antioxidant effects
(36). Administration of the water-soluble inhibitor of p38
caused reductions in 3 plasma products after CLP: extra-
cellular histones, IL-6, and IL-1b, which are known to be
quantitatively linked to the intensity of the sepsis and its
progression (29–31). InCLPWTmice treatedwith the p38
inhibitor, there were substantial reductions in plasma
histones and proinflammatory cytokines (Fig. 3), as well
as reduced evidence of CLP-induced abnormalities in
echo Doppler parameters (Fig. 6).
In our earlier reports, we showed a relationship be-
tween plasma histones and cardiac dysfunction (31), in
which histones caused dysfunction in hearts after poly-
microbial sepsis and alsowhen heartswere perfusedwith
histones, leading to electrical and functional dysfunction.
Such abnormalities could be prevented by infusion of a
neutralizing mAb to histone. We also showed that in vivo
neutralizationof histones in septicmicemarkedly reduced
the parameters of heart dysfunction, as measured by echo
Doppler techniques (31). In the current study, we showed
treatment of CLP mice with the water-soluble p38 in-
hibitor reduced echo Doppler abnormalities in the heart
developing after CLP (Fig. 6) and diminished the evidence
for activation ofMAPKs andAkt in LVCMs (Fig. 5). Itwas
also obvious that the inhibitor decreased LPS-induced
activation of MAPKs and Akt in PEMs stimulated with
LPS (Fig. 4).
However, at this point, the story becomes somewhat
confusing, because the use of the p38 inhibitor not only
suppressed activation of p38 (as determined by immunos-
taining of frozen LV sections fromWT CLP hearts for acti-
vated p38), but also reduced activation of Akt, ERK-1/2,
and JNK-1/2 inLVCMs (Fig. 5).Wewere also able to show
invitro that incubationofperitonealmacrophageswithLPS,
which is a potent microbial mediator and is sometimes
implicated in the pathogenesis of sepsis, resulted in acti-
vationofAkt andall 3MAPKsand that the in vitropresence
of the water-soluble p38 inhibitor reduced activation of all
4 signaling molecules with IC50s between 10 mM (TNF)
and 17 mM (IL-6) (Fig. 4). There are two possible explana-
tions for these findings: the water-soluble p38 inhibitor has
broad inhibitor activities for MAPKs that extend beyond
p38; or alternatively, it is possible that p38 is the first in
a sequence of activation events of signaling molecules
(ERK-1/2, JNK-1/2, and Akt), such that blockade of p38
blocks these downstream activation events. It is difficult
at present to select which early explanation is more likely.
Therapeutic approaches for treatment of septic cardio-
myopathy have been under intensive investigation in re-
cent years. In the past decade, strategic targets were
cardiosuppressive activities in cytokines, suchasTNF (52),
or suppression of signaling pathways leading to NF-kB
activation (53). The multiplicity of cytokines capable of
ultimately causing cardiac or CM dysfunction suggests
that a therapeutic focus on blockade of a single cytokine
probably will not be therapeutically effective. In support
of these reservations, clinical trials in septic patients in
general failed to convincingly demonstrate a beneficial
outcome with TNF or TNF-R blocking agents (54, 55).
However, MAPK signaling may be a promising thera-
peutic target in the setting of septic cardiomyopathy.
Based on information in this report, candidates for ther-
apeutic blockade developing in septic cardiomyopathy
could be p38. Compounds blocking p38 have been de-
veloped for use in Alzheimer’s disease (56), but without
convincing efficacy, whereas drugs such as vemurafenib
(which inhibits phosphorylation of ERK-1/2) have not
been successful in Alzheimer’s disease, but they have not
been evaluated in sepsis. Currently, phase II clinical trials
with vemurafenib are under way in patients with meta-
static melanoma (57). In the heart, inhibition of MAPK
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signal pathways have shown encouraging results in the
case of dilated cardiomyopathy (58), but it is too early to
speculate whether such interventionswould be useful for
treatment of sepsis-induced cardiomyopathy.
CONCLUSIONS
In the setting of polymicrobial sepsis inmice, complement
activation develops and is linked to the development of
septic cardiomyopathy. In the current study, we showed
that the complement anaphylatoxin C5a reacts with its
receptors on CMs. This in vitro incubation of CMs causes
activation of MAPKs and Akt. Furthermore, isolation of
CMs demonstrated phosphorylation of MAPKs (p38,
ERK-1/2, and JNK-1/2) and Akt after sepsis, all of which
wasC5aRdependent. These data together suggest the role
of C5a in activating MAPK and Akt signaling pathways
and the development of cardiac dysfunction after poly-
microbial sepsis. In vivo use of a water-soluble inhibitor of
p38blockedactivation inCMsofMAPKsandAkt in septic
mice. This resulted in protection of CMs from developing
the full expression of defective echo Doppler parameters
after the onset of sepsis.
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